Similar Search Results

Clinical and Economic Comparison of Sertraline and Fluoxetine in the Treatment of Depression: A 6-Month Double-Blind Study in a Primary-Care Setting in France

Boyer, P.; Danion, J.M.; Bisserbe, J.C.; Hotton, J.M.; … - In: PharmacoEconomics 13 (1998) 1 Part 2, pp. 157-169

In a double-blind study in a primary-care setting in France, outpatients fulfilling DSM IV criteria for a major depressive episode were randomised to receive sertraline (50 to 150 mg/day; n = 122) or fluoxetine (20 to 60 mg/day; n = 120). Assessments, including clinical evaluation...

Persistent link: https://www.econbiz.de/10005404832

Cost Effectiveness of Immunoprophylaxis in the Prevention of Recurrent Infectious Rhinitis in Adults

Berdeaux, Gilles; Lafuma, Antoine; Perruchet, Anne-Marie; … - In: PharmacoEconomics 14 (1998) 3, pp. 313-322

Objective: Recurrent infectious rhinitis (RIR) is a frequent disease among adults and constitutes an economic burden for National Sickness Funds (NSF) that might be prevented by immunostimulant therapy. Cost effectiveness of preventive methods should be documented. The aim of this study was to...

Persistent link: https://www.econbiz.de/10005590460

Tapering Off Benzodiazepines in Long-Term Users: An Economic Evaluation

Oude Voshaar, Richard C.; Krabbe, Paul F.M.; Gorgels, … - In: PharmacoEconomics 24 (2006) 7, pp. 683-694

Background: Discontinuation of benzodiazepine usage has never been evaluated in economic terms. This study aimed to compare the relative costs and outcomes of tapering off long-term benzodiazepine use combined with group cognitive behavioural therapy (TO+CBT), tapering off alone (TOA) and usual...

Persistent link: https://www.econbiz.de/10005243152

Sample Size Determination for Cost-Effectiveness Trials

Willan, Andrew R. - In: PharmacoEconomics 29 (2011) 11, pp. 933-949

Methods for determining sample size requirements for cost-effectiveness studies are reviewed and illustrated. Traditional methods based on tests of hypothesis and power arguments are given for the incremental cost-effectiveness ratio and incremental net benefit (INB). In addition, a full...

Persistent link: https://www.econbiz.de/10010614384

Cost Effectiveness of Budesonide/Formoterol for Maintenance and Reliever Therapy versus Salmeterol/Fluticasone plus Salbutamol in the Treatment of Asthma

Johansson, Gunnar; Andreasson, Emma B.; Larsson, Per E.; … - In: PharmacoEconomics 24 (2006) 7, pp. 695-708

Introduction: Budesonide/formoterol (Symbicort(R)) Maintenance And Reliever Therapy (SMART) is an effective and well tolerated treatment option for patients with asthma. We compared the cost effectiveness from a societal perspective of this one-inhaler regimen with that of maintenance...

Persistent link: https://www.econbiz.de/10005449153

A 1-Year Prospective Cost-Effectiveness Analysis of Roflumilast for the Treatment of Patients with Severe Chronic Obstructive Pulmonary Disease

Rutten-van Molken, Maureen P.M.H.; van Nooten, Floortje E. - In: PharmacoEconomics 25 (2007) 8, pp. 695-711

Rationale: Roflumilast is an oral, once-daily phosphodiesterase IV (PDE4) inhibitor under investigation for chronic obstructive pulmonary disease (COPD). This study investigated the cost effectiveness of roflumilast in patients with severe to very severe COPD from the perspective of the UK...

Persistent link: https://www.econbiz.de/10005449249

Escitalopram and Duloxetine in Major Depressive Disorder: A Pharmacoeconomic Comparison Using UK Cost Data

Wade, Alan G.; Fernandez, Jose-Luis; Francois, Clement; … - In: PharmacoEconomics 26 (2008) 11, pp. 969-981

Background: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs) are approved for the treatment of major depressive disorder (MDD). The allosteric SSRI escitalopram has been shown to be at least as clinically effective as the SNRIs venlafaxine...

Persistent link: https://www.econbiz.de/10005590551

Cost-Effective Approaches to the Treatment of Community-Acquired Pneumonia in the Era of Resistance

Kuti, Joseph L.; Capitano, Blair; Nicolau, David P. - In: PharmacoEconomics 20 (2002) 8, pp. 513-528

, most notably the cephalosporin and penicillin derivatives, the macrolide/azalide antibacterials, the newer tetracyclines … antibacterials, thus further increasing costs due to prolonged hospitalisation, treatment of relapses and the use of more expensive … antibacterials. Understanding and maximising the pharmacodynamic properties of the available antibacterials will not only prevent the …

Persistent link: https://www.econbiz.de/10005243094

Piperacillin/Tazobactam: A Pharmacoeconomic Review of its Use in Moderate to Severe Bacterial Infections

Young, Melissa; Plosker, Greg L. - In: PharmacoEconomics 19 (2001) 11, pp. 1135-1175

successfully treated patient than ceftriaxone or cefotaxime, but a slightly higher cost-effectiveness ratio than amoxicillin …, thereby reducing the length of hospital stay and the use of additional antibacterials. Piperacillin/tazobactam has shown …

Persistent link: https://www.econbiz.de/10005243191

An Economic Overview of Chronic Obstructive Pulmonary Disease

Ruchlin, Hirsch S.; Dasbach, Erik J. - In: PharmacoEconomics 19 (2001) 6, pp. 623-642

Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity. Relatively few pharmacoeconomic studies have been conducted on this disease. This article reviews available information about the utilisation of healthcare resources and cost of care, and the cost or cost...

Persistent link: https://www.econbiz.de/10005243194